CMS (Centers for Medicare and Medicaid Services). 2005. Draft Guidance for the Public, Industry, and CMS Staff: Factors CMS Considers in Making a Determination of Coverage with Evidence Development. [Online]. Available: http://www.cms.hhs.gov/coverage/download/guidance.pdf [accessed April 3, 2005].

Durie BG, Katz M, Crowley J. 2005. Osteonecrosis of the jaw and bisphosphonates. New England Journal of Medicine 353:99–102.

Evaluation of Drug Interactions. 2001. St. Louis, MO: First DataBank, the Hearst Corporation.

FDA (Food and Drug Administration). 2003. Drug Interactions: What You Should Know. [Online]. Available: http://www.fda.gov/cder/consumerinfo/druginteractions.htm [accessed February 14, 2006].

FDA. 2005a. FDA unveils Rx safety board, website; postmarket surveillance overhaul next. Pink Sheet 67(8):4.

FDA. 2005b. Adverse Event Reporting System (AERS). [Online]. Available: http://www.fda.gov/cder/aers [accessed February 15, 2006].

FDA. 2005c. Postmarketing Reporting of Adverse Drug Experiences. [Online]. Available: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.80 [accessed March 3, 2006].

FDA. 2005d. MedWatch. [Online]. Available: http://www.fda.gov/medwatch/ [accessed March 4, 2006].

FDA. 2005e. Office of Drug Safety Annual Report FY 2004. [Online]. Available: http://www.fda.gov/cder/Offices/ODS/AnnRep2004/default.htm [accessed March 6, 2006].

FDA. 2006. FDA News: FDA Announces New Prescription Drug Information Format to Improve Patient Safety. [Online]. Available: http://www.fda.gov/bbs/topics/NEWS/2005/NEW01272.html [accessed February 14, 2006].

FTC (Federal Trade Commission). 2001. Hearst Corp. to Disgorge $19 Million and Divest Business to Facts and Comparisons to Settle FTC Complaint. [Online]. Available: http://www.ftc.gov/opa/2001/12/hearst.htm [accessed February 14, 2006].

Gottlieb S. 2005. Opening Pandora’s pillbox: Using modern information tools to improve drug safety. Health Affairs 24(4):938–948.

Goulding MR. 2004. Inappropriate medication prescribing for elderly ambulatory care patients. Archives of Internal Medicine 164:305–312.

Graham DJ, Drinkard CR, Shatin D, Tsong Y, Burgess MJ. 2001. Liver enzyme monitoring in patients treated with troglitazone. Journal of the American Medical Association 286:831–833.

Greenhill LL, Vitiello B, Abikoff H, Levine J, March JS, Riddle MA, Capasso L, Cooper TB, Davies M, Fisher P, Findling RL, Fried J, Labellarte MJ, McCracken JT, McMahon D, Robinson J, Skrobala A, Scahill L, Varipatis E, Walkup JT, Zito JM. 2003. Developing methodologies for monitoring long-term safety of psychotropic medications in children: Report on the NIMH conference, September 25, 2000. Journal of the American Academy of Child and Adolescent Psychiatry 42(6):651–655.

Griffin MR, Stein CM, Graham DJ, Daugherty JR, Arbogast PG, Ray WA. 2004. High frequency of use of rofecoxib at greater than recommended doses: Cause for concern. Pharmacoepidemiology of Drug Safety 13:339–343.

Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, Bates DW. 2003. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. Journal of the American Medical Association 289:1107–1116.

Hansten PD, Horn JR. 2001. Drug Interactions: Analysis and Management. St. Louis, MO: Facts and Comparisons.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement